BridgeBio director has shares withheld for taxes

BridgeBio Pharma director Charles J. Homcy reported a routine tax-withholding transaction related to restricted stock units.

Rhea-AI Filing Summary

BridgeBio Pharma director Charles J. Homcy reported a routine tax-withholding transaction related to restricted stock units. On vesting of 2,196 RSU-based common shares, 788 shares of BridgeBio Pharma, Inc. common stock were withheld at $66.27 per share to cover his tax obligations.

After this non-market disposition, Homcy directly holds 915,886 shares of BridgeBio common stock. This type of Form 4 event reflects compensation and associated taxes rather than an open-market trade expressing a view on the stock.

Insider Trade Summary

Exercise Price or Tax Liability: 788 shares

Exercise Price or Tax Liability 1 txn

Insider HOMCY CHARLES J

Role Director

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	788	$66.27	$52K

Holdings After Transaction: Common Stock — 915,886 shares (Direct)

Footnotes (1)

1. F1. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 2,196 shares of Common Stock underlying the Reporting Person's RSUs.

Key Figures

Shares withheld for taxes: 788 shares Withholding price per share: $66.27 per share RSU shares vested: 2,196 shares +1 more

4 metrics

Shares withheld for taxes 788 shares Common stock withheld for tax obligation on RSU vesting

Withholding price per share $66.27 per share Value used for 788 withheld BridgeBio common shares

RSU shares vested 2,196 shares Common stock underlying RSUs that vested for the director

Shares owned after transaction 915,886 shares Director’s direct BridgeBio common stock holdings post-transaction

Key Terms

RSUs, tax obligation, vesting, tax-withholding disposition

4 terms

RSUs financial

"underlying the Reporting Person's RSUs"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

tax obligation financial

"withheld to satisfy the Reporting Person's tax obligation"

vesting financial

"in connection with the vesting of 2,196 shares"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

tax-withholding disposition financial

"transaction_action": "tax-withholding disposition""

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BridgeBio Pharma (BBIO) director Charles Homcy report?

Charles J. Homcy reported a tax-withholding disposition on BridgeBio Pharma common stock. The company withheld 788 shares when 2,196 RSU-based shares vested, covering his tax obligation rather than reflecting an open-market trade or discretionary sale.

How many BridgeBio Pharma (BBIO) shares were withheld for taxes in this Form 4?

A total of 788 BridgeBio Pharma common shares were withheld to satisfy Charles Homcy’s tax obligation. This occurred in connection with the vesting of 2,196 RSU-based shares and is a non-market disposition typically treated as part of standard equity compensation.

What RSU vesting event triggered the BridgeBio (BBIO) tax withholding?

The withholding was triggered when 2,196 shares of BridgeBio Pharma common stock underlying Charles Homcy’s RSUs vested. To cover the resulting tax liability, 788 of those shares were withheld instead of being delivered to him as freely tradable stock.

How many BridgeBio Pharma (BBIO) shares does Charles Homcy hold after this transaction?

Following the tax-withholding transaction, Charles J. Homcy directly holds 915,886 BridgeBio shares. This figure reflects his position after 788 shares were withheld for taxes tied to the vesting of restricted stock units awarded as part of his compensation.

Was the BridgeBio (BBIO) Form 4 a market sale by Charles Homcy?

No, the Form 4 reflects a tax-withholding disposition, not an open-market sale. The issuer withheld 788 shares at $66.27 per share to pay taxes on vested RSUs, a common administrative step in equity compensation programs rather than an active trading decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 06:46 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HOMCY CHARLES J

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/20/2026		F		788(1)	D	$66.27	915,886	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 2,196 shares of Common Stock underlying the Reporting Person's RSUs.

Remarks:

	/s/ Will Solis, Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)